INTRODUCTION
============

G protein-coupled-receptors (GPCRs) are proteins composed of seven transmembrane alpha helices with an extracellular *N*-terminus and an intracellular *C*-terminus ([@B89]). They represent one of the largest gene families in mammals and humans ([@B54], and references therein). GPCRs can respond to various stimuli such as photons, ions, lipids, peptides, odorants, nucleotides, hormones, or neurotransmitters ([@B17]). There are five human GPCR families: Rhodopsin, Secretin, Adhesion, Glutamate, and Frizzled/Taste2 with the rhodopsin receptor family being the largest. More than half of the 800 human GPCRs are classified as chemosensory taste or olfactory receptors ([@B54]; [@B45]). The remaining human GPCRs -roughly 370- may be involved in pathophysiological processes and are therefore potentially drugable targets. Indeed, metabolic, inflammatory, infectious or neurodegenerative diseases as well as cancer all involve a plethora of GPCRs ([@B45]). As many GPCRs belong to neuromodulatory systems ([@B112]), a large number of them are targeted by drugs in the context of nervous system disorders such as pain, drug addiction, anxiety, depression, sleep disorders, and neuroendocrine deregulation ([@B45]). Altogether, GPCRs represent the targets of about one third of marketed drugs ([@B78]).

Understanding the roles of GPCRs requires both in depth small scale investigation and overview. Indeed, GPCR expression, function, modulation, and trafficking properties remain difficult to fathom and reflect the complex, highly regulated pathways in which they are involved. The study of GPCRs in physiology and disease therefore requires integrative and functional systems. This is especially true when considering the central nervous system (CNS) where neuronal networks are complex and intermingled. It is therefore of utmost importance to identify and delineate cells that express the GPCR of interest. In the majority of studies, mapping GPCR expression was overcast by poor antibody specificity. The measure of this limitation was only fully appreciated when genetically modified mice which were deficient for the GPCR of interest became available, emphasizing the insufficient specificity of the commonly used antibodies, thereby prompting the search for new technologies to monitor receptor trafficking, decipher activated intracellular signaling cascades or investigate functional outcomes of GPCR activation in integrated systems, and particularly in neuronal networks ([@B66]). Among the options which were being explored, fluorescent proteins (FPs) isolated from natural organisms attracted special interest as they appeared to be very promising tools to achieve these goals. There are many advantages to using fluorescent molecular tags; the inherent fluorescence is directly visible, chemically resistant to fixation and can be used in time-course studies in living cells for tracking receptor trafficking events ([@B48]).

The Green FP (GFP) was the first FP used in biology. This protein is composed of 238 amino acids (roughly 27 kDa) and was isolated from the jellyfish *Aequorea victoria* ([@B98], for review see [@B108]). A mutant form of GFP called enhanced GFP (eGFP) was later generated, with improved quantum yield efficiency and higher solubility, making eGFP a popular reporter molecule ([@B18]). The additional mutants that were created offer a large palette of fluorescence, ranging from violet to far red, thus opening new perspectives, including the possibility of co-expressing two or more FP in the same cell, whereby protein interactions could be investigated ([@B43]). Likewise, this can be achieved by simultaneously expressing eGFP and mcherry, a stable monomeric mutant derived from the red fluorescent protein (RFP) DsRed, the latter was isolated from the coral *Discosoma sp.* ([@B12]; [@B96]). Additional variants derived from the GFP or DsRed were also generated and possess fast maturation, improved pH stability and photostability (reviewed in [@B97]; [@B103]). The development of these FPs has been paralleled by technological advances in the field of live cell imaging that have brought high quality approaches for analysis of biological processes in a time- and space-dependent manner ([@B76]).

Validation of drug targets and pharmacological mechanisms cannot be achieved without *in vivo* preclinical studies for which mouse models provide a mammalian background and genetic tools of great value ([@B21]; [@B9]). In order to address GPCR function *in vivo,* tracking endogenous receptors with FPs therefore represents indisputable added value. In the following sections, we will review and comment on the use of FPs that has helped to shed light on endogenous GPCR function *in vivo.*

*IN VIVO* EXPRESSION OF FP UNDER GPCR PROMOTER
==============================================

FROM TRANSGENIC TO KNOCK-IN MOUSE LINES
---------------------------------------

Transgenic mouse lines expressing FPs under the control of promoters for a GPCR or an endogenous peptide were created. A number of reporter mice generated using bacterial artificial chromosomes (BACs) were part of a project called gene expression nervous system atlas (GENSAT) <http://www.gensat.org/index.html> ([@B36]) that produced an important set of data relative to gene expression which could be used for deciphering the developmental implications and network dynamics of selected genes of interest. On the account that specific CNS genes are most often expressed in a particular cell population or anatomically defined structure, tandem dimer Tomato (td-Tomato), a RFP, or eGFP-labeling of these cells renders analysis of the anatomical, physiological and biomolecular properties of a chosen subtype of neurons accessible. Overall, transgenic reporter mouse lines have proven to be extremely useful for the precise mapping of GPCR and endogenous ligands expression in the nervous system, and are suitable for analysis of cell populations ([@B44]).

The shortcomings of the transgenic mouse models are, however, manifold ([@B42]). (1) Transgenic expression results in overexpression compared to wild type animals. (2) Low efficiency of transmission to offspring may be caused by mosaic expression of the transgene in founder animals. Indeed, high copy number insertion of transgenes is more vulnerable to epigenetic silencing, which reduces the transgene expression level in successive generations. (3) Expression in unexpected tissues or timeframes may result from transgene insertion in genomic regions containing an endogenous promoter or enhancer. (4) Silencing or ectopic expression can be caused by positional effects. Transgene insertion can take place into transcriptionally inactive regions of the genome, or can be affected by neighboring repressor sites. Transgene insertion being, in essence, random, the possibility of disrupting the normal genome is very high. As a consequence, the erratic nature of the transgene insertion may result in unpredicted and/or detrimental phenotypes and off-target effects. As an example, many groups used BAC transgenic mice expressing eGFP driven by the promoter for either D~1~ or D~2~ receptors, the dopamine receptor 1 or 2, respectively ([@B56]; [@B7]; [@B111]; [@B106]; [@B52]; [@B13]). Mainly, work published using these two BAC transgenic mice successfully identified neurons expressing dopamine receptors and delineated dopaminergic connectivity in the CNS. However, [@B52] brought evidence of molecular and behavioral alterations in Drd2-eGFP BAC transgenic mice comprising novel environment hyperactivity, reduced locomotor response to cocaine, and D~2~ receptor agonist hypersensitivity. These effects were presumably due to unfortunate insertion of the BAC, which caused receptor overexpression ([@B52]).

KNOCK-IN MICE: TOWARD MORE SPECIFIC MODELS
------------------------------------------

To overcome the limitations associated with the use of transgenic mice, efforts were made to generate knock-in animals in which a FP is introduced at the locus of interest by homologous recombination. Several strategies are used (see **Figure [1](#F1){ref-type="fig"}**). Models in which an FP is expressed either under the control of an endogenous GPCR promoter are valuable and reliable tools for localization and characterization of cell population which express the GPCR of interest. However, such strategies present a significant drawback since the GPCR is non-functional following partial or total replacement of its coding sequence by the FP coding one. The FP is thus expressed in appropriate cells, but the precise subcellular localization and function of the receptor cannot be examined and the final outcome, in the case of homozygous animals, is the absence of the functional GPCR, equivalent to a knock-out phenotype. This limitation can be circumvented by the introduction of an internal ribosomal entry site (IRES) sequence, whereby expression of the endogenous GPCR is maintained and the chosen FP is expressed under control of the endogenous promoter.

![**Schematic diagram of genetic constructions of knock-in mice expressing a fluorescent protein (FP) under the control of an endogenous GPCR promoter. (A)** Endogenous GPCR gene layout. **(B)** Knock-in FP expressed under the control of the endogenous GPCR promoter: the endogenous GPCR gene is replaced by the FP coding sequence. **(C)** The FP coding sequence is knocked into the truncated gene coding for the native GPCR, resulting in genetic invalidation of the receptor. **(D)** Insertion of an internal ribosomal entry site (IRES) downstream of the endogenous GPCR gene, ahead of the FP coding sequence. Native GPCR expression is maintained, and the FP is also expressed under the control of the endogenous GPCR promoter. **(E)** The FP sequence is inserted in frame in place of the stop codon in the endogenous GPCR gene giving rise to a fluorescent fusion protein in which the FP is fused to the *C*-terminus of the functional GPCR in conditions of native expression.](fphar-05-00289-g001){#F1}

### Chemokine receptors

[@B47] published the first knock-in mouse in which an FP was expressed under a GPCR promoter. The aim was to track cells which expressed the Fractalkin (CX~3~C) chemokine receptor CX~3~CR1, using a GFP knock-in strategy by replacing the first 390 bp of exon 2 of the *CX3CR1* gene that encodes the receptor *N*-terminus by a eGFP-coding sequence, enabling direct identification of peripheral blood cells and brain microglia expressing CX~3~CR1 (see **Table [1](#T1){ref-type="table"}**). In heterozygous animals, CX~3~CR1 expression remained detectable because these CX~3~CR1^+/GFP^ heterozygous animals possess one allele for fluorescence visualization of cells expressing the GPCR of interest and one allele for expression of the functional receptor. Since CX~3~CR1 and its ligand Fractalkin play a role in immunological and inflammatory processes, this model was used to investigate microglia proliferation during early embryonic spinal cord invasion ([@B88]) neuron-glia interactions in the context of nerve injury or neuroinflammation ([@B29]) and in neurodegenerative diseases such as Alzheimer's disease ([@B28]), or Parkinson's disease ([@B114]).

###### 

Knock-in mice expressing fluorescent proteins under the control of G protein-coupled receptor (GPCR) endogenous promoters.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeted GPCR                                         Fluorescent protein   Identified cell type                Model                                       Therapeutic potential                          Reference
  ----------------------------------------------------- --------------------- ----------------------------------- ------------------------------------------- ---------------------------------------------- -----------
  **Insertion of FP sequence at the GPCR gene locus**                                                                                                                                                        

  Chemokine CX~3~CR1                                    eGFP                  Immune cells                        Peritonitis Nerve injury                    Neuroinflammation Neurodegenerative diseases   [@B47]

                                                                              Microglia                                                                       Population dynamics in embryonic development   [@B88]

                                                                              Microglia                           Neurodegeneration                           Alzheimer                                      [@B28]

                                                                              Microglia                           Neuroinflammation                           Parkinson                                      [@B114]

  Chemokine CCR2                                        RFP                   Immune cells                        Experimental autoimmune encephalomyelitis   Neuroinflammation\                             [@B92]
                                                                                                                                                              Neurodegenerative diseases                     

  Chemokine CX~3~CR1 x\                                 eGFP\                 Immune cells                        Experimental autoimmune encephalomyelitis   Neuroinflammation Neurodegenerative diseases   [@B92]
  Chemokine CCR2                                        RFP                                                                                                                                                  

                                                                              Myeloid cells Microglia             Experimental autoimmune encephalomyelitis   Population dynamics in embryonic development   [@B71]

  Oxytocin                                              Venus                 Brain distribution                  Anxiety related                             Psychiatric disorders                          [@B126]

                                                                              Spinal cord distribution                                                        Nociception/pain                               [@B123]

  Mrgprd                                                eGFPf                 Sensory projections to epidermis                                                Nociception/pain                               [@B127]

                                                                              Sensory projections to tooth pulp                                               Nociception/dental pain                        [@B16]

  Taste TasR1                                           mcherry               Taste cells in taste buds and\                                                  --                                             [@B115]
                                                                              peripheral tissue                                                                                                              

  Taste Tas2R131                                        hrGFP                 Taste cells in taste buds and\                                                  --                                             [@B115]
                                                                              peripheral tissue                                                                                                              

  Taste TasR1 x\                                        mcherry\              Taste cells in taste buds and\                                                  --                                             [@B115]
  Taste Tas2R131                                        hrGFP                 peripheral tissue                                                                                                              

  **GPCR-IRES-FP expression**                                                                                                                                                                                

  Mas-related Mrgprd                                    eGFPf                 Sensory projections to epidermis                                                Nociception/pain                               [@B127]

  Cannabinoid CB1                                       Td-Tomato             Neurons                             Chronic cocaine injection                   Drug addiction                                 [@B122]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A follow-up to this knock-in mouse was published in 2010. In their paper, [@B92] designed a mouse with another single FP, RFP (a DsRed variant) replacing the first 279 base pairs of the open reading frame coding for the chemokine receptor type 2 (CCR2), and crossed the heterozygous CCR2^+/RFP^ and homozygous CCR2^RFP/RFP^ knock-in animals with the previously published CX~3~CR1^GFP/GFP^ homozygous animals, in order to obtain heterozygous double knock-in animals CX~3~CR1^+/GFP^CCR2^+/RFP^. The two chemokine receptors are expressed by distinct monocyte populations, therefore the red and green FPs constitute an elegant "two-colored" mouse model which was ideally suited for immunological studies (see **Table [1](#T1){ref-type="table"}**). Indeed, because the immune system is constituted of cells that circulate in blood and lymph vessels, mature cells do not constitute a solid organ and are not restricted by connective tissue, therefore immune cell tracking is essential. Both the double heterozygous knock-in animals and the first mouse line (CX~3~CR1^+/GFP^ knock-in), were used to study and adequately quantify macrophage and monocyte population dynamics in a model of autoimmune tissue inflammation (experimental autoimmune encephalomyelitis), which recapitulates an animal model of multiple sclerosis (MS). In a subsequent study, the same group unveiled myeloid lineage and microglial chemokine receptor changes at embryonic stages 8.5--13.5, monitored CNS colonization by cells of interest, during development and in an MS model using adult mice ([@B71]). The knock-in models thus yielded exciting and fundamental results relative to the identification of cells expressing the designated GPCRs, and a fine description of cellular population changes in various disease paradigms.

### Oxytocin receptors

[@B125] engineered a mouse line in which a 5′ fragment of exon 3 of the oxytocin receptor (*OTR*) gene was replaced by a sequence coding for Venus FP, a yellow FP variant ([@B74]). The recombined allele did not encode functional OTR but heterozygous animals retained radiolabelled oxytocin binding patterns through the intact allele, while enabling direct visualization of Venus in oxytocin expressing cells ([@B125]). Immunohistochemical analysis of brain sections from these animals revealed that there was a high expression of Venus (hence OTR) in monoaminergic areas of the brain in agreement with *in situ* hybridization (ISH) studies ([@B110]). However, the approach provided more sensitive detection of OTR expression by identifying additional areas and cells expressing Venus fluorescence among which serotoninergic ones. This study was the first to show evidence for interaction between oxytonergic and serotonergic systems in a pathway, which modulates anxiety. In a following study, these knock-in mice were used to map OTR expression in the spinal cord; shedding light on the modulatory role of oxytocinergic networks involved in spinal cord functions, such as nociception ([@B123]).

### Taste receptors

Sensing of the chemical categories which are responsible for sweet, sour or umami taste is specifically encoded by GPCRs expressed on primary taste neurons ([@B60]). The taste receptor family 1 (Tas1r) belongs to class C GPCRs and function as obligatory heteromers, meaning that two GPCRs of different subtypes are associated and interact to form a functional entity. The taste receptor family 2 (Tas2r), on the other hand, are currently classified among class A GPCRs ([@B2]).

In order to study the distribution of taste receptors in the mouse gustatory tissue, Voigt and collaborators engineered two knock-in mouse lines which they subsequently crossed in order to obtain double knock-in animals in which the open reading frame encoding the receptor was replaced by the sequence coding for the mcherry or humanized Renilla (hr)GFP under the control of Tas1r1 (umami taste receptor) or Tas2r131 (bitter taste receptor) promoters, respectively ([@B115]). This approach permitted identification of cells expressing mcherry under the control of the Tas1r1 promoter in the lingual papillae, soft palate, fungiform and foliate papillae, confirming previous findings ([@B46]; [@B101]) but also in extra-gustatory tissues (lung epithelium, testis, thymus) which had not been investigated before ([@B115]). Expression of hrGFP under the control of Tas2r131 promoter was in accordance with previously findings describing taste receptor distributions ([@B5]), showing abundant hrGFP expression in taste buds of the posterior tongue, vallate palate and foliate palate. In addition, it uncovered, for the first time, expression restricted to only half of the bitter sensor cells ([@B115]). Double knock-in animals lacked both taste receptors, but expressed FPs in the targeted cells \[verified by reverse transcription polymerase chain reaction (RT-PCR), ISH and immunohistochemistry\]. This genetic labeling technique served for population distribution studies, which was until then unachievable, given the fact that Tasr expression is sparse in cells, and that the available antibodies lack specificity. The double knock-in animals yielded a valuable and detailed cartography of taste receptors in the mouse, and revealed that distinct chemosensory cell populations mediate specific and non-overlapping taste qualities.

### Mas-related-G-protein coupled receptors

Mas-related-G-protein coupled receptor member D (Mrgprd) belongs to a GPCR family of approximately 50 members, related to *Mas1* (oncogene-like MAS), called Mrgs. Mrgs are suspected to be involved in development, regulation and function of nociceptive neurons or nociceptors ([@B20]) and are expressed in a subset of nociceptors, which are small diameter primary sensory neurons in dorsal root ganglia (DRG) directly involved in processing nociceptive stimuli, especially itch ([@B61]).

[@B127] observed similar expression patterns of the eGFPf (a farnesylated form that anchors the FP to the cytoplasmic leaflet of the lipid bilayer) in nociceptors, and projections of the sensory neurons to the epidermis using knock-in mice in which the open reading frame coding for Mrgprd is replaced by the sequence encoding the eGFPf or knock-in animals in which the eGFPf sequence is inserted behind an IRES element downstream of the mouse Mrgprd gene ([@B127]). This demonstrates that both strategies can be equally used for cellular mapping. In addition, similar projection profiles in the epidermis validated the eGFPf knock-in mouse for axonal tracing by comparison with the widely used human placental alkaline phosphatase tethered to the extracellular surface of the plasma membrane by a glycophosphatidylinositol linkage.

In a later study, the knock-in mouse model expressing eGFPf at the Mrgprd locus was used to identify non-peptidic nociceptive neurons of trigeminal ganglia innervating tooth pulp ([@B16]). This opens future application of this model to study the role and function of the targeted GPCR in dental pain.

### Cannabinoid receptors

The endocannabinoid system plays roles in memory, appetite, stress and immune processes, as well as motivation and emotional responses and modulates the effects of some drugs of abuse ([@B80]; [@B104]). In the nucleus accumbens (NAc), a brain structure which has a crucial role in reward processing and a decisive influence on emotional and motivational responses, cannabinoid receptor 1 (CB1) expression is limited but nevertheless essential for cocaine-induced reward in mice ([@B67]). In order to further identify and delineate the cellular and electrophysiological properties of CB1 receptor expressing cells in the NAc, [@B122] designed a knock-in mouse line in which an IRES element ensures expression of both CB1 receptors and td-Tomato under the control of the CB1 promoter. Importantly, this mouse line still expressed functional CB1 receptors. Neurons expressing CB1 receptors were readily visualized in the NAc and their distribution was in accordance with previous data on CB1 receptor localization using ISH or immunohistochemistry ([@B64]; [@B109]). This mouse line enabled to identify of cells and to explicitly demonstrate biochemical and signaling properties of a particular neuronal population of fast-spiking interneurons in the NAc which impacts on the NAc projections and connectivity. Results also revealed functional impact of cocaine on these neurons ([@B122]).

GPCR-FP FUSION FOR *IN VIVO* FUNCTIONAL AND MAPPING STUDIES
===========================================================

INITIAL VALIDATION OF GPCR-FP FUSIONS IN HETEROLOGOUS SYSTEMS
-------------------------------------------------------------

Fusions between a GPCR and an FP as tools to monitor the GPCR subcellular localization and trafficking were first studied in heterologous systems. Two fusion options were considered: either the FP at the *N*-terminus or at the *C*-terminus. A vast majority of GPCRs do not have cleavable *N*-terminus signal sequences that target them to the plasma membrane. Introduction of a foreign sequence ahead of their *N*-terminus has been shown to disrupt surface addressing, and correct membrane targeting and insertion therefore requires introduction of an additional foreign signal sequence in front of the fusion construct ([@B68]). If proper cell surface expression is indeed restored, introduction of such a signal sequence nonetheless strongly impacts on the relative ratio between surface expression and intracellular distribution by substantially increasing the amount of protein at the cell surface ([@B23], and references therein). Hence, such fusion proteins are not well suited to mimic the responses of endogenous GPCRs to agonist stimulation and were not used for *in vivo* studies.

Concerns have also been raised regarding in frame insertion of the FP at the *C*-terminus of the GPCR by substitution of the stop codon. The presence of a 27 kDa beta barrel at the intracellular extremity of the GPCR could indeed interfere with intracellular scaffold partners and modify signaling or internalization processes thus defeating the object when studying GPCR signaling properties. However, many studies performed in mammalian cells on a large number of GPCRs strongly suggest that addition of GFP at the *C*-terminus does not significantly affect subcellular distribution in the basal/unstimulated state, ligand binding or agonist-induced receptor phosphorylation and internalization, (for review [@B48]). [@B69] expressed β~1~- and β~2~-adrenergic receptors fused to a *C*-terminal eGFP mutant in human embryonic kidney (HEK 293) cells. These authors concluded that the presence of the eGFP did not influence ligand binding but decreased the agonist-induced internalization kinetics without affecting the intracellular fate of the receptor. Trafficking of the fusion protein was qualitatively maintained, but was quantitatively slightly modified compared to native proteins. This study therefore supports the use of such fusions to monitor endogenous receptor subcellular localization. Similarly, the genetic construction encoding the delta opioid (DOP) receptor fused with eGFP protein at the *C*-terminus was expressed in transfected HEK 293 cells, and the fusion did not alter opioid ligand binding affinity or signaling ([@B95]). This construct was later successfully used to express a functional DOP-eGFP fusion in mice by knocking the modified sequence into the endogenous DOP receptor locus ([@B95], see below).

In some cases, however, FP fusion at the GPCR C-terminus had deleterious effects. Defective targeting to the cell surface was reported for the melanocortin 2 receptor fused to the GFP in HEK 293 cells ([@B90]) and no recycling was observed for the muscarinic M4 receptor fused to a *C*-terminal red variant of GFP in neuroblastoma/glioma hybrid cells (NG108-15 cells; [@B63]). In both cases, impairment was more likely to be due to gross overexpression rather than fusion of the FP to the *C*-terminus. High levels of expression of a GPCR in a non-native environment can indeed artificially elicit properties and interactions that would not occur *in vivo*. Moreover, cell lines used for heterologous expression may provide different intracellular machinery for complex protein folding or post-translational modifications compared to naturally producing cells. This represents an additional limitation to the study of GPCR functions and prompted to develop *in vivo* approaches.

FROM TRANSGENIC TO KNOCK-IN MOUSE LINES
---------------------------------------

[@B79] reported a transgenic mouse model of a fluorescent tagged GPCR. The construct they described was composed of a 3.4 kb fragment of the mouse endogenous α1B adrenoceptor promoter, the human α1B adrenoceptor coding sequence with *C*-terminal fusion eGFP sequence. The resulting founder lines were characterized, and high expression levels were observed in all tissues that naturally express α1B adrenoceptors by fluorescence microscopy. Binding affinities and internalization profiles were similar to those of endogenous receptors. With this study, [@B79] reported the first mouse model expressing a GPCR tagged with eGFP as a transgenic approach for *in vivo* GPCR localization studies. The generation of knock-in animals represented a further improvement by enabling for the first time to track down endogenous receptors, which has opened a new era for pharmacological research.

KNOCK-IN HUMANIZED RHODOPSIN FUSED WITH A FLUORESCENT PROTEIN (hRho-eGFP)
-------------------------------------------------------------------------

[@B14] mouse lines expressing human rhodopsin-eGFP were engineered using different knock-in strategies. All mouse lines showed decreased expression levels of the fusion protein relative to the endogenous mouse rhodopsin. Comparing the different homozygote mouse lines enabled to correlate the decrease in human rhodopsin--eGFP expression to the increased rate of retinal degeneration, providing a model of human diseases. More recently, using a human mutant rhodopsin allele \[proline-to-histidine change at codon 23 (P23H) rhodopsin\] which induces mislocalization and degradation of the human protein, the research group generated a knock-in mouse line which modeled a common cause of autosomal dominant retinitis pigmentosa ([@B85]). In humans, mutation Q344X is responsible for a severe early onset form of retinitis pigmentosa. The Q344X mutation introduces a premature stop codon that prevents GFP expression in the human rhodopsin-eGFP construct. Knock-in animals expressing this mutant construct were used to monitor eGFP fluorescence recovery as an index of the frequency and timing of somatic mutations in the rhodopsin gene ([@B93]). These mouse lines provided substantial and valuable data concerning rhodopsin distribution in the retina (for references, also see **Table [2](#T2){ref-type="table"}**), and were advantageously implemented for non-invasive measurement by illuminating the mouse retina in live animals with blue light ([@B121]). They will provide a means to assess the impact of future gene-targeting treatment strategies for retinal degeneration ([@B38]; [@B93]).

###### 

Knock-in mice expressing GPCR-fluorescent protein fusions.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fusion construct         Biological readout                                                                                                                                         Reference
  ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  hRhodopsin-eGFP          Retinal degeneration kinetics\                                                                                                                             [@B14]
                           (model of recessive retinitis pigmentosa)                                                                                                                  

                           Distribution, membrane structure, and trafficking of rhodopsin (model of retinitis pigmentosa)                                                             [@B38]

  P23H-hRhodopsin-eGFP     Degeneration and degradation kinetics of rhodopsin (model of common cause of autosomal dominant retinitis pigmentosa)                                      [@B85]

  Q344X-hRhodopsin-eGFP    DNA repair in photoreceptors cells during retinogenesis (degeneration and degradation kinetics in a model of severe early-onset of retinitis pigmentosa)   [@B93]

  DOP-eGFP                 Receptor distribution:\                                                                                                                                    [@B95]; [@B94]), [@B25]
                              --central nervous system                                                                                                                                

                              -- hippocampus                                                                                                                                          [@B24], [@B86], [@B87])

                              -- dorsal root ganglia                                                                                                                                  [@B94]; [@B4]

                              -- mechanosensors in the skin                                                                                                                           [@B4]

                              -- myenteric plexus                                                                                                                                     [@B81]

                           Correlation between behavioral desensitization and receptor internalization                                                                                [@B95]; [@B82], [@B84])

                           Biased agonism at the receptor\                                                                                                                            [@B82], [@B84])\
                              -- pharmacological drugs\                                                                                                                               [@B26]
                              -- endogenous opioid peptides                                                                                                                           

                           Behaviorally controlled receptor subcellular distribution                                                                                                  [@B26]; [@B8], [@B55]

  MOP-mcherry              Receptor distribution in the central and peripheral nervous systems                                                                                        [@B25]

  MOP-mcherry x DOP-eGFP   MOP-DOP neuronal co-expression in the brain                                                                                                                [@B25]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OPIOID RECEPTORS
----------------

The opioid system modulates a wide range of physiological states, of which nociception, reward, mood, stress, neuroendocrine physiology, immunity, autonomic functions such as gastro-intestinal transit ([@B50]; [@B118]; [@B15]; [@B62]). Opioid receptors are members of the class A GPCR family, mu (MOP), delta (DOP) and kappa (KOP) opioid receptors couple to inhibitory heterotrimeric inhibitory G protein, and have high sequence homology ([@B1]).

### Mapping of receptor expression with neuronal resolution

[@B95] generated a DOP-eGFP knock-in mouse line by homologous recombination in which the coding sequence for the DOP receptor fused to its *C*-terminus to the eGFP was inserted at the *Oprd1* locus.

Delta opioid-eGFP knock-in mice proved very helpful to map DOP receptors in the nervous system and remedy the lack of highly specific antibodies (see **Table [2](#T2){ref-type="table"}**). In the peripheral nervous system, DOP-eGFP receptors were detected in cell bodies of specific peripheral sensory neuronal populations which process sensory stimuli, namely mostly in large diameter myelinated (Neurofilament 200 positive), and in small diameter unmyelinated non-peptidergic (Isolectin B4 positive) neurons ([@B94]; [@B4]). The expression pattern of DOP-eGFP receptors was also reported in mechanosensory organs in the skin ([@B4]). Another study focused on the distribution of DOP-eGFP in enteric neurons with DOP-eGFP expression mainly in secretomotor neurons of the submucosal plexus of the digestive tract ([@B81]). The observed distribution reflects functional roles of DOP receptors in inhibition of intestinal motility and absorption.

In the CNS, DOP-eGFP mapping was performed in the brain and spinal cord ([@B25]). Detailed DOP-eGFP expression was also reported in the hippocampus, where functional DOP-eGFP was found to be mainly expressed in GABAergic interneurons, mostly parvalbumin-positive ones ([@B24]; [@B87]). The DOP-eGFP knock-in mice also enabled to resolve the debate concerning the presence of DOP receptors in principal cells. The absence of colocalization with calbindin ([@B24]) and presynaptic expression restricted to afferents to glutamatergic principal cells established that no functional DOP receptors are expressed under basal conditions in those cells ([@B86]). These results are consistent with a modulation of principal cell activity in the hippocampus by DOP receptors, and therefore an impact of the receptors in learning and memory.

More recently, a knock-in mouse line expressing a MOP receptor fused with a RFP at the C-terminus, MOP-mcherry, was generated by [@B25]. At the *Oprm1* locus, mcherry cDNA was introduced into exon 4 of the MOP gene in frame and 5′ from the stop codon. This FP is monomeric and highly photostable, and the strong red signal of MOP-mcherry fusion protein enabled direct identification of neurons expressing MOP in the nervous system ([@B25]). The authors compiled the DOP-eGFP and MOP-mcherry distributions in a neuroanatomical atlas available at <http://mordor.ics-mci.fr>

Several studies in heterologous systems or cell culture had suggested that MOP and DOP receptors may interact to form heteromers ([@B113]; [@B91]; [@B100]) but their existence *in vivo* remains debated. Co-immunoprecipitation studies performed on tissue from spinal cord or DRGs also hinted at close physical proximity between the two receptors in these areas ([@B35]; [@B124]). In addition, MOP-DOP heteromers had been detected in some brain areas using specific antibodies ([@B40]). Recently, extensive mapping of MOP-DOP neuronal colocalization using double knock-in mice co-expressing DOP-eGFP and MOP-mcherry provided sound data to investigate MOP-DOP physical proximity and functional interactions. In the hippocampus, a brain area where the two receptors are highly co-expressed, co-immunoprecipitation experiments using antibodies raised against the FPs indeed confirmed physical proximity ([@B25]). These animals will now be useful to address MOP-DOP specificities in ligand binding, signaling and trafficking as well as functional output and to investigate the potential of MOP-DOP heteromers as a novel therapeutic target.

### *In vivo* trafficking, desensitization and behavioral output

The DOP-eGFP mouse line is the first example of the use of a knock-in line to study GPCR functions *in vivo* ([@B95]). DOP agonist-induced internalization was observed *in vivo* upon activation by the alkaloid \[(+)-4-\[(alphaR)-alpha-((2S,5R)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-meth oxybenzyl\]-N,*N*-diethylbenzamide\] (SNC-80) and the endogenous peptide Met-enkephalin ([@B95]). The two agonists induce receptor internalization in heterologous systems with receptor phosphorylation as the first step of a cascade of events leading to termination of G protein dependent signaling, receptor removal from the cell membrane and trafficking to intracellular compartments ([@B27]; [@B116]; [@B117]). DOP-eGFP mice revealed that these agonists also induce receptor phosphorylation, internalization via clathrin coated pits *in vivo* and degradation in the lysosomal compartment in the brain ([@B95]; [@B82]; [@B26]) and peripheral nervous system in the myenteric plexus ([@B81]) and DRGs ([@B94]). Moreover, these animals prove to be instrumental to decipher molecular mechanisms underlying receptor desensitization leading to a loss of responsiveness of the receptor upon stimulation by an agonist. [@B95] were indeed able, for the first time, to establish the correlation between receptor trafficking *in vivo* and the behavioral response: namely that the receptor internalization induced by acute administration of the agonist SNC-80 was responsible for the observed locomotor desensitization. This paper was followed by additional studies exploring the consequences of receptor pharmacological stimulation in more detail, in particular the concept of biased agonism.

G protein-coupled receptors have a flexible and highly dynamic nature ([@B72]) which enables a given ligand to show functional selectivity, that is, preferential activation of signal transduction pathways, otherwise termed biased agonism ([@B77]; [@B34]; [@B49]). DOP-eGFP mice offer the possibility of addressing this concept *in vivo* and to link it to a functional response. DOP-eGFP mice were used to analyze the properties of two DOP receptor agonists possessing similar signaling potencies and efficacies but with different internalization profiles ([@B82]). SNC-80 and N,*N*-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide (AR-M100390), with high and low internalization properties respectively, were systemically administered to mice, and receptor trafficking was correlated to induced anti-allodynic effect in the context of inflammatory pain ([@B82]). As expected, acute SNC-80 administration resulted in receptor phosphorylation, decreased G protein coupling and receptor degradation in the lysosomal compartment, leading to desensitization with loss of anti-allodynic properties. On the other hand, acute injection of AR-M100390 did not result in receptor phosphorylation, did not reduce G protein coupling, did not induce receptor internalization or desensitization but retained analgesic properties. This study demonstrated that DOP receptor localization determines its function *in vivo* and highlights the importance of receptor tracking in order to extricate behavioral and cellular correlates of specific agonist properties ([@B82]).

In a following study, DOP-eGFP mice were used to assess the physiological impact of distinct signaling pathway recruitment and/or adaptive responses upon chronic administration of two DOP receptor agonists ([@B84]). Chronic administration of SNC-80, which has high internalization properties, led to marked receptor downregulation and degradation in SNC-80-tolerant animals. Receptor internalization prevented any additional activation through physical disappearance from the cell surface leading to general desensitization, as assessed by thermal and mechanical analgesia, locomotor activity and anxiety-related behavior. On the other hand, chronic administration of AR-M100390, with weak internalization properties, did not cause changes in DOP-eGFP localization and induced tolerance restricted to analgesia, with no effect on locomotor activity or anxiolytic responses. These data show that a selective internalization-independent tolerance was elicited and suggest the occurrence of adaptative mechanisms that are network dependent. These findings reinforce the importance of understanding agonist specific signaling underlying biased agonism and tolerance. Considering that drug design has focused on offering orthosteric or allosteric modulators of GPCRs ([@B9]), research groups need to explore the downstream signaling cascades of these drugs in more detail in order to understand and target the molecular events which underlie their efficacy. This is an essential progress for the understanding of drug action and opens new possibilities for drug design.

Direct visualization of the receptor also permitted to decipher the functional role of delta receptors in neuronal networks and to understand the complex relation between behavior and receptor subcellular distribution. Of particular interest is the observation that DOP subcellular distribution is modified in two brain areas involved in the processing of information associated with emotional value or predicted outcome. The CA1 area of the hippocampus is known to operate as a coincidence detector that reflects association of the context with strong emotional stimuli of positive or aversive value ([@B22]). Accordingly, increased c-Fos immunoreactivity revealed activation of this region in a drug-context association paradigm, and DOP-eGFP internalization in this area therefore suggested a modulatory role of the receptor in behavioral responses linked to context-induced withdrawal ([@B26]). Along the same line, persistent increase of DOP-eGFP expression at the cell surface of cholinergic interneurons was induced by conditioned training in the NAc shell, which is involved in decision making and predictive reward evaluation upon pavlovian conditioning ([@B8]; [@B55]).

Finally, the knock-in strategy revealed that the DOP-eGFP internalization profile in response to endogenous opioid release is distinct from what is observed upon pharmacological stimulation ([@B26]). Indeed, only part of the receptor population present at the cell surface underwent internalization under physiological conditions. This observation further highlights the need to take into account the extent of changes that drug administration induces in receptor cellular distribution.

### Methodological improvements

Interestingly, DOP-eGFP knock in mice also bring useful technical insight. During the process of acute brain slice preparation for electrophysiological recordings, DOP-eGFP revealed spontaneous receptor internalization ([@B87]). This event was likely due to high glutamatergic activity in the hippocampus upon slicing that leads to exitoxicity. Direct visualization of the receptor therefore revealed a bias associated with previously unrecognized receptor trafficking that can now be addressed by initiating optimization of slice preparation conditions for electrophysiological recording ([@B87]). This observation may be of particular relevance when addressing cellular responses elicited by drug application.

CONCERNS ABOUT THE USE *IN VIVO* OF GPCR-FP FUSIONS FOR FUNCTIONAL STUDIES
==========================================================================

Despite the undeniably wide advances which have been and will be brought by genetically engineered mice encoding fluorescent endogenous GPCRs, concerns were raised regarding the inherent consequences of genetic manipulation. The possibility that the observed localization does not entirely reflect the wild type receptor distribution appears irrelevant since both MOP-mcherry and DOP-eGFP receptor distributions in the brain are in full agreement with reports in mice and rats based on ligand binding ([@B51]; [@B99]; [@B37]; [@B59]), GTPγS incorporation ([@B105]; [@B83]) or mRNA detection \[[@B33]; [@B65]; [@B11]; for a review see ([@B58])\]. Also, in a more detailed study, DOP-eGFP expression in the hippocampus, mainly in parvalbumin-positive GABAergic interneurons ([@B24]), was corroborated by ISH studies on DOP receptors ([@B102]).

In the peripheral nervous system, despite previous reports suggesting SP-dependent trafficking of DOP receptors to the cell membrane ([@B39]), [@B94] reported that DOP-eGFP almost never co-localized with substance P (SP) in peripheral sensory neurons ([@B94]), a finding that was debated by others ([@B120]). A more recent study addressed this discrepancy by comparing DOP-eGFP cellular distribution to that of the native DOP receptor using an ultrasensitive and specific ISH technique, which can detect single mRNA molecules ([@B4]). Patterns of DOP-eGFP distribution and *Oprd1* mRNA expression were found to be very similar and detectable in the same neuronal populations, namely mostly in large diameter myelinated cells (Neurofilament 200 positive), and in small diameter unmyelinated non-peptidergic neurons (isolectin B4 positive; [@B4]). These data unambiguously confirm that the expression profile of the fluorescent constructs mimics the endogenous one and that fluorescent knock-in mice can be reliably used for mapping receptors in the central and peripheral nervous system.

Regarding functional aspects, there has been no evidence so far of any overt phenotypical or behavioral differences between the DOP receptor knock-in strain and wild type animals ([@B95]; [@B82], [@B84]; [@B87]), despite a twofold increase in mRNA and protein levels as well as increased G protein activation compared to wild type animals ([@B95]). However, the possibility that the subcellular distribution of the fluorescent fusion does not recapitulate that of the native untagged receptor is still debated. Indeed, high surface expression of DOP-eGFP is observed under basal conditions in several brain regions, particularly in the hippocampus ([@B94]; [@B24], [@B25]; [@B26]). This does not correlate with previous studies on wild type receptors using electron microscopy or fluorescent ligands that indicated a predominant intracellular localization under basal conditions and surface recruitment upon chronic morphine or chronic pain condition ([@B11]; [@B73]; [@B31]; for review see [@B10]; [@B32]). Surface expression of DOP-eGFP, however, varies across CNS regions and neuronal type whereas high fluorescence is always visible within the cytoplasm ([@B25]). Accordingly, high surface expression appears to be restricted to some neuronal types such as GABAergic interneurons in the hippocampus or large proprioceptors in DRGs ([@B95]; [@B25]). In many areas where DOP receptors are highly expressed such as the striatum, the basal ganglia, the amygdala or the spinal cord, DOP-eGFP is not readily detected at the cell surface ([@B25]) suggesting that DOP-eGFP intracellular localization is predominant in those neurons. Importantly, surface expression of DOP-eGFP can be augmented under physiological stimulation ([@B8]; [@B55]; see above) or increased upon chronic morphine treatment as previously reported for wild type receptors (Erbs et al., unpublished data), strongly supporting that the fused FP does not impact on the native subcellular distribution of the receptor and that the latter can be modulated according to the physiological state or modified upon pharmacological treatment.

In the case of MOP-mcherry knock-in mice, the red fluorescent signal is stronger inside the cell than at the plasma membrane ([@B25]). This distribution reflects actual receptor intracellular distribution, as evidenced by comparison with MOP-specific immunohistochemistry in heterozygous mice, which confirms that the fusion protein does not cause defective receptor localization or surface trafficking ([@B25]). Importantly, MOP-mcherry retained unchanged receptor density as well as \[D-Ala^2^, N-MePhe^4^, Gly-ol\]-enkephalin (DAMGO) binding and efficacy and agonist-induced internalization compared to MOP. Moreover, behavioral effects of morphine in knock-in mice were similar to wild type animals: acute and chronic thermal analgesia, physical dependence, sensitization and rewarding properties revealed no significant differences with wild type animals ([@B25]). These data suggest that predominant intracellular localization of MOP-mcherry receptors with low expression at the cell surface indeed reflect endogenous wild type receptor subcellular distribution under basal conditions, as observed in enteric neurons ([@B81]). In addition, internalization kinetics of MOP-mcherry upon activation by the agonist DAMGO in hippocampal primary neuronal cultures ([@B25]) were similar to those reported for DAMGO promoted internalization of endogenous wild type receptors in the rat spinal cord ([@B107]) and in organotypic cultures of guinea pig ileum ([@B70]) or to Fluoro-dermorphin-induced sequestration in rat cortical primary neurons ([@B57]). This supports once again the use of fluorescent knock-in mice to study endogenous receptor trafficking. Of note, DAMGO promotes Flag-MOP receptor internalization with similar kinetics in transfected striatal primary neurons ([@B41]), in adenovirus infected primary cultures from DRG ([@B119]) or in neurons of the locus coeruleus in brain slices from transgenic FLAG-MOP receptor mice ([@B3]).

CONCLUSIONS AND IMPACT FOR DRUG DESIGN
======================================

Fluorescent knock-in mice represent a substantial technical improvement in basic science. Precise identification and localization of the neurons expressing the GPCR of interest and reliable monitoring of receptor subcellular localization are both essential in understanding the physiopathological roles of endogenous GPCRs. This was greatly anticipated, given the difficulties encountered by many on the grounds of poor specificity of the available antibodies for GPCR targeting. The main surprising finding is maybe that the presence of the FP at the *C*-terminus of the GPCR does not significantly alter the behavioral output: this observation fully validates the technology. However, fluorescent knock-in animals available to date target a handful of class A GPCRs only. The potency of the model being now clearly established, one would expect rapid expansion to other receptors, in particular those with critical roles in human pathologies. Forefront candidates include class C GABA~B~ and metabotropic glutamate receptors, both of which are involved in a wide range of neurological disorders such as schizophrenia, neuropathic pain, cerebral ischemia, mood disorders and substance abuse ([@B6]; [@B19]; [@B53]). Fluorescent knock-in animals would enable to revisit heterodimerization mechanisms, membrane targeting and cellular distribution patterns of these obligatory heterodimers *in vivo*. Furthermore, the relation between multimer scaffold composition, in particular GABA~B~ auxiliary subunits, and neuronal or synaptic functions could also be readily examined to refine our current understanding of the variations in pharmacological and functional responses mediated by native receptors ([@B30]).

The knock-in mice bearing GPCR-FP fusions already contributed to understanding the fundamental concepts of distinct signaling or regulatory responses recruited by different agonists of the same GPCR. These essential aspects of biased agonism are a growing central concern in drug discovery in the hope of developing strategies that ally high efficacy with low or no side effects. In addition, GPCR-FP fusions could bring considerable knowledge regarding functional aspects of receptor activity and internalization to evaluate the therapeutic potency of allosteric modulators. This very active field of research is mainly targeting class C GPCRs with well identified allosteric and orthosteric binding sites such as metabotropic glutamate or GABA~B~ receptors but relevance for class A GPCRs is attracting increasing attention ([@B75]). Direct visualization of the neurons of interest, either by FP under the control of a GPCR promoter or by expression of the GPCR fluorescent construct, also represents a significant breakthrough by making subsequent targeted investigations available. This includes electrophysiological recordings on previously identified cell, cell isolation by fluorescence-activated cell sorting for further biochemical (Western Blotting) and molecular (RT-PCR) downstream analysis or highly specific and efficient immunoprecipitation of the interacting partners. The presence of the FP also gives access to imaging techniques with which receptor population tracking within membranes can be achieved, by fluorescence recovery after photobleaching or fluorescence resonance energy transfer. The latter also opens ways to identify heteromer formation between GPCRs or between a GPCR and a ligand-gated channel and to investigate *in vivo* their intracellular fate and impact on signaling cascades. All these technological developments will undeniably contribute to deepening our current knowledge of GPCR controlled molecular and cellular processes and ultimately will benefit to drug design and screening.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors acknowledge the support of CNRS, the FRM grant (DPA20140629804).

[^1]: Edited by: *Marianthi Papakosta, Pfizer, USA*

[^2]: Reviewed by: *Enrico Sanna, University of Cagliari, Italy; Ioannis N. Charalampopoulos, University of Crete, Greece*

[^3]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology.
